Welcome to our dedicated page for Keros Therapeutics news (Ticker: KROS), a resource for investors and traders seeking the latest updates and insights on Keros Therapeutics stock.
Keros Therapeutics, Inc. (Nasdaq: KROS) is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders. The company’s mission focuses on addressing high unmet medical needs through innovative therapeutic solutions.
At the forefront of Keros’ pipeline is KER-050, a protein therapeutic product candidate aimed at treating low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes (MDS) and myelofibrosis. KER-050 is currently in Phase 2 clinical trials, with promising data presented at the 65th American Society of Hematology meeting showcasing its potential to ameliorate ineffective hematopoiesis and improve patient outcomes.
Another key product in development is KER-012, a small molecule being developed for the treatment of pulmonary arterial hypertension (PAH) and cardiovascular disorders. This candidate is also in Phase 2 trials and has shown encouraging preliminary results, particularly in treating bone loss disorders such as osteoporosis and osteogenesis imperfecta.
KER-047, another small molecule candidate, targets anemia and the rare genetic disorder, fibrodysplasia ossificans progressiva (FOP). Currently in Phase 1 clinical trials, KER-047 aims to address significant gaps in treatment for these conditions.
Financially, Keros reported a net loss of $39.4 million for the third quarter of 2023, attributed to increased research and development efforts. Despite this, the company maintains a solid cash balance of $287.9 million as of September 30, 2023, expected to fund operations into the fourth quarter of 2025. The recent public offering of $120 million in common stock further strengthens their financial position.
Keros’ strategic partnerships and collaborations play a crucial role in its development strategy. The company’s agreement with Hansoh (Shanghai) Healthtech Co., Ltd. in 2021 for manufacturing technology transfer is a significant step towards commercial scalability.
The company’s commitment to advancing its pipeline and achieving clinical milestones is evident through its continuous updates and transparent communication with stakeholders. Upcoming milestones include updates on the KER-050 and KER-012 programs, reflecting Keros’ proactive approach in driving innovation and improving patient lives.
Keros Therapeutics remains a leader in leveraging the transforming growth factor-beta (TGF-β) family of proteins, aiming to provide meaningful and potentially disease-modifying benefits to patients.
Keros Therapeutics, a clinical-stage biopharmaceutical company (Nasdaq: KROS), announced the appointment of Alpna Seth, Ph.D., to its Board of Directors, effective May 1, 2023. Dr. Seth brings extensive experience in drug development and global operations, having previously served as CEO of Nura Bio and COO of Vir Biotechnology. Her expertise includes leadership roles at Biogen, where she was instrumental in drug commercialization and development. Keros focuses on innovative treatments for hematological, pulmonary, and cardiovascular disorders, with notable candidates such as KER-050 for cytopenias and KER-012 for pulmonary arterial hypertension. The addition of Dr. Seth is seen as a strategic move to enhance the company's capabilities at a crucial time.
Keros Therapeutics (KROS) reported its fourth quarter and full year 2022 financial results, revealing a net loss of $29.7 million for Q4 and $104.7 million for the entire year, significantly up from $6.9 million and $58.7 million in 2021, respectively. The increase is attributed to heightened research and development costs, particularly for the Phase 2 trials of KER-050 targeting myelodysplastic syndromes and myelofibrosis. Keros maintained a strong cash position of $279.0 million as of December 31, 2022, sufficient to fund operations into Q3 2025. The company outlined several key milestones for 2023, including expanded trials for KER-050 and KER-047.
Keros Therapeutics, Inc. (Nasdaq: KROS), a biopharmaceutical company, announced that its President and CEO Jasbir S. Seehra, Ph.D., will participate in a fireside chat at Cowen’s 43rd Annual Health Care Conference on March 8, 2023, at 11:10 a.m. Eastern time. The event will provide insights into Keros’ innovative treatments for hematological, pulmonary, and cardiovascular disorders. A live audio webcast can be accessed here, with an archived replay available on Keros’ website for up to 90 days post-event.
Keros Therapeutics (Nasdaq: KROS), a clinical-stage biopharmaceutical company, announced participation in a fireside chat at the SVB Securities Global Biopharma Conference on February 14, 2023, at 3:40 p.m. ET. President and CEO Jasbir S. Seehra, Ph.D., will represent the company.
A live audio webcast of the event will be available here, with an archived replay accessible on Keros' website for up to 90 days post-event. Keros focuses on novel treatments for hematological, pulmonary, and cardiovascular disorders, including lead candidates KER-050, KER-047, and KER-012.
Keros Therapeutics presented new data from its ongoing Phase 2 clinical trials during the 2022 ASH Annual Meeting, focusing on KER-050 for myelodysplastic syndromes (MDS) and myelofibrosis (MF), and KER-047 for iron-refractory iron deficiency anemia (IRIDA). Results showed a 51.7% erythroid response rate in MDS patients receiving KER-050, with treatment well-tolerated and no serious adverse events reported. Initial data for KER-047 indicated potential iron redistribution. The company maintains a focus on developing treatments for hematological disorders with high unmet medical needs.
Keros Therapeutics, Inc. (Nasdaq: KROS), a clinical-stage biopharmaceutical company, announced that President and CEO Jasbir S. Seehra, Ph.D., will participate in upcoming fireside chats at the Piper Sandler 34th Annual Healthcare Conference and the 5th Annual Evercore ISI HealthCONx Conference.
Piper Sandler Conference: November 29, 10:00 a.m. ET. Live audio webcast available here.
Evercore ISI Conference: December 1, 8:50 a.m. ET. Live audio webcast available here.
Keros Therapeutics, Inc. (KROS) announced promising preclinical results for RKER-012, a novel treatment for pulmonary arterial hypertension (PAH). The findings, presented at the American Heart Association 2022 Scientific Sessions, show that RKER-012 improved cardiac and pulmonary function in a rat model of PAH. The treatment significantly reduced inflammatory and fibrotic markers, indicating potential for treating not just PAH but other inflammatory diseases. KER-012's development targets crucial pathways involved in fibrosis and cardiac hypertrophy.
Keros Therapeutics (KROS) announced the acceptance of five abstracts for presentation at the 64th American Society of Hematology Annual Meeting, scheduled for December 10-13, 2022. The presentations include preliminary results from Phase 2 trials for KER-050, aimed at treating myelodysplastic syndromes and myelofibrosis, and KER-047 for iron-refractory iron deficiency anemia. CEO Jasbir S. Seehra highlighted this as an opportunity to share important updates and anticipates releasing additional efficacy data for KER-050 by mid-December.
FAQ
What is the current stock price of Keros Therapeutics (KROS)?
What is the market cap of Keros Therapeutics (KROS)?
What is Keros Therapeutics’ main focus?
What are the key products in Keros Therapeutics’ pipeline?
What recent achievements has Keros Therapeutics reported?
What is the financial condition of Keros Therapeutics?
How is Keros Therapeutics advancing its clinical trials?
What partnerships does Keros Therapeutics have?
What disorders does KER-050 target?
What is the significance of Fast Track designation for KER-050?
When can we expect updates on KER-012?
What role does the TGF-β family of proteins play in Keros Therapeutics’ research?
